On October 16th, 2Firsts reported that a manufacturing product of Zhuhai Qisitech (referred to as "Zhuhai Qisi") was included in the "red list" incident. (Click here to read the article).
In response to the incident, Zhuhai Qisi issued a statement today (October 17th), addressing two key points. The specifics of their response are as follows:
1. The product in question does not belong to our company.
2. The management team of Zhuhai Qisi has attached great importance to this matter, conducting a thorough analysis and investigation in a timely manner while actively implementing response measures. As a global aerosol contract manufacturing company, Zhuhai Qisi has always placed product quality and compliance at a high priority. In response to the recent FDA announcement, the company has swiftly initiated an emergency plan, demonstrating a firm attitude and efficient actions in addressing the issue.
Currently, Zhuhai Qisi has decisively stopped production of the products involved, actively contacted customers and brands, and jointly carried out an investigation to cope with this crisis, making every effort to minimize the adverse impact on the market. At the same time, Zhuhai Qisi is actively communicating with the FDA. We also hope that in the future, the FDA will conduct more comprehensive evaluations and considerations for every product from China.
In conclusion, we will continue to enhance communication and cooperation with customers and regulatory authorities, providing reliable and compliant products to the market and consumers with a high sense of responsibility.
(Above is the original response from Zhuhai Qisi)
2Firsts will continue to follow the development of the event and provide updates on relevant news.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
